TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has made notable progress in its intellectual property portfolio with the acceptance of a patent application in Australia and the issuance of a Notice of Allowance from the Japan Patent Office for its RNA-based therapeutic platform technologies. These developments are significant for the company's focus on immuno-oncology and RNA treatments for high-risk and advanced cancer.